Latest Earnings Results: Q2 '26
Estimated EPS
-$0.12
Reported EPS
-$0.12
Surprise
+3.28%
Estimated Rev
$0M
Reported Rev
---
Surprise
---
• Reported GAAP EPS of -$0.12 up 50.00% YoY • Shattuck Labs expects that current cash and cash equivalents and short-term investments of approximately $208.3 million as of June 30, 2026, will be sufficient to fund operations into 2029.
Bullish Takeaway
Shattuck Labs reported positive Phase 1 clinical data for SL-325, remains on track for Phase 2b trial initiation, and strengthened its balance sheet to fund operations through the year 2029.
Bearish Takeaway
Shattuck Labs reported an increased net loss and higher research and development expenses, while facing structural risks regarding the unpredictable relationship between preclinical results and future clinical trial outcomes.
Generated by Stocktwits using AI and company-reported earnings data for Q2 '26. This recap is intended to help readers understand the quarter quickly. Verify key figures in the linked source materials; the summary may contain errors and is not investment advice.
Historical Earnings
Quarterly
Annual
EPS
Revenue
| Fiscal Period | Estimated | Reported | Surprise | Result |
|---|---|---|---|---|
Q3 '26 | -$0.10 | -- | -- | N/A |
Q2 '26 | -$0.12 | -$0.12 | 3.28% | BEAT |
Q1 '26 | -$0.14 | -$0.13 | 6.11% | BEAT |
Q4 '25 | -$0.14 | -$0.12 | 11.88% | BEAT |
Q3 '25 | -$0.15 | -$0.14 | 5.79% | BEAT |